Editorial

Although the journal *Mediators of Inflammation* will continue to publish research papers, starting with this issue Volume 7 Number 1 (February 1998), several changes have been made.

- The Journal has been sold by Thomson's Rapid Science Publishers to Carfax Publishing Ltd. This has not interfered with the publication of research papers which had already been submitted, although a slight delay may have occurred. The Editors would like to thank the staff at Thomson's Rapid Science Publishers for all their help in setting up the publication of an excellent new journal.
- Although the Journal has survived the first 6 years of publication there is no time for a sabbatical year! With growing interest in the field of immunopharmacology of inflammation, research papers have been submitted from all over the world. Since we have also published some high-standing reviews, citation of the Journal is increasing, leading to an impact factor which will hopefully further increase and settle it amongst other immunology journals covering similar subjects.
- The format of the Journal has changed, and the cover has been redesigned accordingly to illustrate the crucial role some cells play during both acute and chronic phases of the inflammatory process. The publication of a journal also has an initial, sub-acute and chronic phase. Following submission of a paper, copies are sent to referees, who normally respond within two weeks: facsimile transmissions

are of crucial importance in order to improve the speed of publication. The most time-consuming operations in the publication process are typesetting, printing, binding and mailing. Carfax will do everything possible to aim for a publication speed of less than 5 months from submission to publication, which is extremely good for a bimonthly journal.

- Authors who would like to submit a research paper are asked to include a textfile copy on floppy disk or to transfer simultaneously their files by e-mail in order to diminish hands-on time per accepted paper.
- The number of Editorial Board members has been reduced and the Editorial positions have been rearranged as follows:

Editor (Executive): Dr Freek J. Zijlstra

Editor (News and Reviews):

Professor Rod J. Flower

Editor (Current affairs and development):

Professor Boris B. Vargaftig

Editor (Honorary Consulting):

Professor Ivan L. Bonta

Editor (North America): Dr Peter Vadas

We look forward to receiving innovative papers for *Mediators of Inflammation* on all aspects of the immunology, molecular biology, and pharmacology of inflammation.

Dr Freek J. Zijlstra
Editor (Executive)